Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
UC San Diego Medical Center
mi
from
San Diego, CA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
UC San Diego Medical Center
mi
from
San Diego, CA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Medical Associates Research Group
mi
from
San Diego, CA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Medical Associates Research Group
mi
from
San Diego, CA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
University of Colorado, Boulder
mi
from
Boulder, CO
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
mi
from
Boulder, CO
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
University of Miami Hospital
mi
from
Miami, FL
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
mi
from
Miami, FL
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Atlanta Medical Center, Inc.
mi
from
Atlanta, GA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Atlanta Medical Center, Inc.
mi
from
Atlanta, GA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Liver Center of Atlanta
mi
from
Atlanta, GA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Liver Center of Atlanta
mi
from
Atlanta, GA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Rush University Medical Center
mi
from
Chicago, IL
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
mi
from
Chicago, IL
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Loyola University Medical Center
mi
from
Proviso, IL
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Loyola University Medical Center
mi
from
Proviso, IL
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
University of Kansas Medical Center
mi
from
Kansas City, KA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
University of Kansas Medical Center
mi
from
Kansas City, KA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
University of Louisville Hospital
mi
from
Louisville, KY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
University of Louisville Hospital
mi
from
Louisville, KY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Alton Ochsner Medical Foundation Hospital
mi
from
New Orleans, LA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Alton Ochsner Medical Foundation Hospital
mi
from
New Orleans, LA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Tulane University Medical Center
mi
from
New Orleans, LA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Tulane University Medical Center
mi
from
New Orleans, LA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Umass Memorial Medical Center
mi
from
Worcester, MA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Umass Memorial Medical Center
mi
from
Worcester, MA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Henry Ford Hospital
mi
from
Detroit, MI
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Henry Ford Hospital
mi
from
Detroit, MI
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
St. Louis Medical Center
mi
from
St. Louis, MO
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
St. Louis Medical Center
mi
from
St. Louis, MO
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Bronx Municipal Hospital Center
mi
from
Bronx, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Bronx Municipal Hospital Center
mi
from
Bronx, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Cornell University, Weill Medical College
mi
from
New York, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Cornell University, Weill Medical College
mi
from
New York, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
New York University
mi
from
New York, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
New York University
mi
from
New York, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Concorde Medical Group
mi
from
New York, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Concorde Medical Group
mi
from
New York, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
New York Medical College
mi
from
Valhalla, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
New York Medical College
mi
from
Valhalla, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Consultants for Clinical Research
mi
from
Cincinnati, OH
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Consultants for Clinical Research
mi
from
Cincinnati, OH
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Cleveland Clinic Florida
mi
from
Weston, FL
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Cleveland Clinic Florida
mi
from
Weston, FL
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Albert Einstein College of Medicine
mi
from
Bronx, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Albert Einstein College of Medicine
mi
from
Bronx, NY
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Baylor All Saints
mi
from
Fort Worth, TX
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Baylor All Saints
mi
from
Fort Worth, TX
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Univ of Texas Galveston
mi
from
Galveston, TX
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Univ of Texas Galveston
mi
from
Galveston, TX
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Research Specialists of Texas
mi
from
Houston, TX
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Research Specialists of Texas
mi
from
Houston, TX
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
St Luke's Health System
mi
from
Kansas City, MO
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
St Luke's Health System
mi
from
Kansas City, MO
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Veterans Affairs Medical Center - East Orange
mi
from
East Orange, NJ
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - East Orange
mi
from
East Orange, NJ
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
University of Utah
mi
from
Salt Lake City, UT
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
University of Utah
mi
from
Salt Lake City, UT
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Metropolitan Research
mi
from
Fairfax, VA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Metropolitan Research
mi
from
Fairfax, VA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Inova Fairfax
mi
from
Falls Church, VA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Inova Fairfax
mi
from
Falls Church, VA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Virginia Commonwealth University (VCU)
mi
from
Richmond, VA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Virginia Commonwealth University (VCU)
mi
from
Richmond, VA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders
Status: Archived
Updated: 1/1/1970
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Alabama Liver & Digestive Specialists (Alds)
mi
from
Montgomery, AL
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
Alabama Liver & Digestive Specialists (Alds)
mi
from
Montgomery, AL
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
Mayo Clinic Phoenix
mi
from
Phoenix, AZ
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
University of Arizona
mi
from
Tucson, AZ
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
University of Arizona
mi
from
Tucson, AZ
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
eStudySite
mi
from
Chula Vista, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
eStudySite
mi
from
Chula Vista, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Scripps HealthCare
mi
from
LaJolla, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
Scripps HealthCare
mi
from
LaJolla, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Synergy Clinical Research Center
mi
from
National City, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
Synergy Clinical Research Center
mi
from
National City, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
RESEARCH and EDUCATION, INC
mi
from
San Diego, CA
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140
Status: Archived
Updated: 1/1/1970
RESEARCH and EDUCATION, INC
mi
from
San Diego, CA